Terms: = Cervical cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Clinical Outcome
4 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. Identification of an immune signature to predict poor clinical outcome in cervical cancer.
Yan W; Jin H; Zhang X; Long S; Xia Q; Meng D; Ding B; Li D; Ma J; Cao J; Wang S
Epigenomics; 2021 Jun; 13(11):891-907. PubMed ID: 33955785
[No Abstract] [Full Text] [Related]
3. Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy.
Liang Y; Yu M; Zhou C; Zhu X
Diagn Pathol; 2020 Jun; 15(1):67. PubMed ID: 32493336
[TBL] [Abstract] [Full Text] [Related]
4. Immune Checkpoint Inhibitors in Gynecological cancers: Update of Literature and Perspectives of clinical Research.
Gadducci A; Guerrieri ME
Anticancer Res; 2017 Nov; 37(11):5955-5965. PubMed ID: 29061774
[TBL] [Abstract] [Full Text] [Related]
